Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients

Saudi Journal of Gastroenterology

Volumn 21, Issue 3, 2015, Pages 146-151

  Yu, Hyung Min ^a   Kwon, So Young ^a   Kim, Jiwan ^a   Chung, Hyun Ah ^a   Kwon, Se Woong ^a   Jeong, Taek Gun ^a   An, Sang Hee ^a   Jeong, Gyung Won ^a   Yun, Seon Ung ^a   Min, Jae Ki ^a   Kim, Jeong Han ^a   Choe, Won Hyeok ^a  

^a Konkuk University School of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; efficacy; entecavir; safety; tenofovir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; TENOFOVIR; ANTIVIRUS AGENT; GUANINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHROTOXICITY; SEROCONVERSION; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD; ANALOGS AND DERIVATIVES; BLOOD; COHORT ANALYSIS; DRUG EFFECTS; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; METABOLISM; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TENOFOVIR; VIRAL LOAD;

EID: 84930428026     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.157558     Document Type: Article

References (28)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500.
2. Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: Hepatitis B. Korean J Hepatol 2009;15:S13-24.
3. Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS; Organizing Committee of Japan-Korea Liver Symposium. Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology 2008;75:13-6.
4. Yuen MF, Seto WK, Chow DH, Taui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-303.
5. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
6. Korean association for the study of the Liver. KASL clinical practice guidelines: Management of chronic hepatitis B. Clin Mol Hepatol 2012;18:109-62.
7. Abaalkhail F, Elsiesy H, AlOmair A, Alghamdi MY, Alalwan A, AlMasri N, et al. SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol 2014;20:5-25.
8. Jenh AM, Pham PA. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2010;8:1079-92.
9. Honkoop P, De Man RA. Entecavir: A potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs 2003;12:683-8.
10. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30.
11. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Longterm monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14.
12. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55.
13. Snow-Lampart A, Chappell BJ, Curtis M, Zhu Y, Myrick F, Schawalder J, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients mono infected with chronic hepatitis B virus. Hepatology 2011;53:763-73.
14. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10:941-6.
15. Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, et al. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol 2014;60:715-22.
16. Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007;81:3992-4001.
17. Lampertico P. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. J Hepatol 2009;50:644-7.
18. Dogan UB, Kara B, Gumurdulu Y, Soylu A, Akin MS. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos (t) ide-naive patients with chronic hepatitis B. Turk J Gastroenterol 2012;23:247-52.
19. Guzelbulut F, Ovunc AO, Oetinkaya ZA, Senates E, Gökden Y, Saltürk AG, et al. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B. Hepatogastroenterology 2012;59:477-80.
20. Ke W, Liu L, Zhang C, Ye X, Gao Y, Zhou S, et al. Comparison of efficacy and safety of Tenofovir and entecavir in chronic hepatitis B virus infection: A systematic review and meta-analysis. PLoS One2014;9:e98865.
21. Ceylan B, Yardimci C, Fincanci M, Eren G, Tozalgan U, Muderrisoglu C, et al. Comparison of tenofovir and entecavir in patients with chronic HBV infection. Eur Rev Med Pharmacol Sci 2013;17:2467-73.
22. Bae SH, Yoon SK, Jang JW, Kim CW, Nam SW, Choi JY, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005;20:816-20.
23. Kim H, Jee YM, Song BC, Shin JW, Yang SH, Mun HS, et al. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 2007;50:52-7.
24. Lee JM, Ahn SH, Chang HY, Shin JE, Kim DY, Sim MK, et al. Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry. Korean J Hepatol 2004;10:260-70.
25. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49:S185-95.
26. Heathcore EJ, Marcellin P, Buti M. Three-year efficacy and safety through 4 years of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-43.
27. Gao L, Trinh HN, Li J, Nguyen MH. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther 2014;39:629-37.
28. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 2013;58:505-13.